Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1467335 in Healthy Japanese Male Volunteers With Multiple Oral Doses at the Highest Dose in Caucasian for Comparison (Randomised, Double-blind, Placebo-controlled Trial)
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2018
At a glance
- Drugs BI 1467335 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 03 Jan 2018 Status changed from active, no longer recruiting to completed.
- 07 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jun 2017 Status changed from not yet recruiting to recruiting.